New Report: 800+ Rare Disease Medicines in Clinical Development or Regulatory Review
A New Report Shows Promise for Patients
What You'll Find In this FREE The Analysis Group report:
  •  Details of the state of the drug pipeline
  •  Insights into such areas as the therapeutic areas being explored
  •  The distribution of clinical research projects by phase
  •  The number of potential first-in-class medicines
  •  Several new areas of scientific opportunity being applied to advance treatments
    The biopharmaceutical pipeline contains thousands of significant and innovative new treatments with the potential to address unmet medical needs, save lives and improve patients’ health. A new report by the Analysis Group, “The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development,” examines the state of the drug development pipeline and provides insights into new approaches researchers are pursuing.
    Key findings from the full report include:
    •  As of August 2016, there were more than 6,300 products in clinical development globally
    •  Taking into account that there may be clinical trials underway in more than one indication for a given molecule, these products correspond to over 9,500 projects in clinical development
    •  Development projects were distributed across many therapeutic areas, from cancer to cardiovascular disease and diabetes, to neurology
    •  Approximately three-quarters (74%) of clinical-phase projects were potentially first-in-class
    •  Of the projects in clinical development, 822 were determined to be covered by an orphan drug designation awarded by the FDA
    •  A range of novel scientific approaches to address various diseases and conditions were being pursued in clinical development
    Request your copy of the full report here:
    GOBOLDLY (TM) by America's Biopharmaceutical Research Companies
    Copyright 2017 - PhRMA
    Powered By